- What Is an Investigator's Brochure?
- What an Investigator's Brochure Must Contain
- Why the IB Matters More Than Most Sponsors Realize
- Common Mistakes FIH Sponsors Make With the IB
- The IB in the Context of a First-in-Human Program
- What a Strong IB Looks Like in Practice
- Regulatory Alignment Across Jurisdictions
- Frequently Asked Questions
If you are preparing for a first-in-human trial, the investigator's brochure will be one of the first documents your regulatory reviewers, ethics committees, and clinical sites ask for. Yet many early-stage sponsors treat it as an afterthought — something to pull together in the weeks before submission rather than a document built in parallel with protocol development.
That approach creates delays. This article explains what an investigator's brochure is, what it must contain, and why having a complete, current version ready before you engage a CRO or submit to a regulatory authority is not just good practice — it is a prerequisite for moving fast.
What Is an Investigator’s Brochure?
An investigator's brochure (IB) is a compiled document that summarizes all clinical and non-clinical data relevant to studying an investigational product in human subjects. It gives the principal investigator and site staff what they need to understand the rationale for the trial, the expected risks and benefits, and how to manage participants safely.
For drug and biologic trials, the IB is required under ICH E6(R2) GCP guidelines. For medical device trials, the analogous document is often the Investigational Device Exemption (IDE) application or the Investigational Plan — but the underlying need is the same. Investigators require a consolidated reference that explains the device, its preclinical performance data, and the scientific basis for proceeding to human use.
The IB is not a marketing document. It is a scientific summary written for clinicians and regulators.
What an Investigator’s Brochure Must Contain
ICH E6(R2) sets out the standard structure. A complete IB typically includes:
- Title page and table of contents — sponsor name, product name or code, version number, and date
- Confidentiality statement — restricting use to investigators and ethics committees
- Summary — a brief synopsis of the physical, chemical, pharmaceutical, and pharmacological properties, and their clinical implications
- Introduction — the product name, active ingredients, pharmacological class, and rationale for conducting research
- Physical, chemical, and pharmaceutical properties — relevant to safety and handling, particularly important for radiopharmaceuticals and implantable devices
- Non-clinical studies — pharmacology, toxicology, pharmacokinetics, and metabolism data from animal or in vitro studies, with a discussion of findings and their relevance to human use
- Effects in humans — any prior human data, including compassionate use or early feasibility results if available
- Summary of data and guidance for the investigator — a concise risk-benefit assessment and practical guidance on dosing, monitoring, and adverse event management
- References — cited literature supporting the above sections
For medical devices specifically, the non-clinical section should include bench testing results, biocompatibility data, and any animal study outcomes. The summary should address the device's intended use and the basis for the proposed first-in-human use parameters.
Why the IB Matters More Than Most Sponsors Realize
It Is the Foundation for Ethics Committee Review
Before any clinical site in Panama, Chile, El Salvador, or the Dominican Republic can enroll a patient, the local ethics committee and national regulatory authority must review and approve the study. That review is grounded in the IB. Reviewers use it to assess whether the preclinical safety package justifies exposing humans to the investigational product.
An incomplete or poorly organized IB does not just slow down approval — it can trigger requests for additional data that take months to generate. In jurisdictions where regulatory approvals can move in 30 to 90 days, a weak IB is often the single biggest bottleneck sponsors create for themselves.
It Sets the Risk Framework for Your Protocol
The IB and the clinical protocol are co-dependent documents. Stopping rules, dose escalation criteria, adverse event monitoring thresholds, and inclusion/exclusion criteria should all be traceable back to the risk signals identified in the IB.
If you write the protocol before the IB is complete, you are making safety assumptions without a documented evidentiary basis. Regulators will notice. Ethics committees will ask where those assumptions came from.
It Protects Investigators and Sponsors
When an adverse event occurs during a trial, the IB is the reference point for determining whether the event was anticipated. An event that matches a known risk documented in the IB is handled differently from one that was not disclosed. A thorough, honest IB protects investigators by giving them accurate expectations — and it protects sponsors by demonstrating that known risks were disclosed to the site before enrollment began.
It Must Be Updated Throughout the Trial
The IB is a living document. ICH E6(R2) requires that it be reviewed at least annually and updated whenever new information materially changes the risk-benefit picture. If new safety signals emerge from parallel studies while your trial is ongoing, the IB must reflect that, and sites and ethics committees must receive updated versions promptly.
Sponsors who treat the IB as a document written once and filed away will find themselves out of compliance when auditors review the trial master file.
Common Mistakes FIH Sponsors Make With the IB
Starting too late. The IB should be drafted in parallel with preclinical work, not after it concludes. If animal studies are still running, draft the structure now and populate it as data becomes available.
Omitting negative findings. Regulators and ethics committees are not looking for a document that presents only favorable data. Omitting unfavorable preclinical findings does not make them disappear — it raises questions about sponsor credibility and can result in clinical holds.
Using inconsistent terminology. The product name, dose units, and adverse event terminology in the IB should match the protocol exactly. Discrepancies between documents create confusion during review and can delay approval.
Failing to localize for the operating jurisdiction. If your trial is running in Latin America, the IB may need to be available in Spanish depending on the country and the ethics committee's requirements. Sponsors who assume an English-only document will suffice in every jurisdiction often discover this requirement at the worst possible moment.
Not assigning version control. Every IB update must carry a new version number and date. Without it, sites may be working from outdated information without realizing it.
The IB in the Context of a First-in-Human Program
For a startup running its first FIH trial, the IB is one of nine workstreams that need to come together before a patient can be enrolled. It sits upstream of protocol development, site selection, ethics committee submission, and regulatory authority review.
The bioaccess® FIH-12 program is structured around exactly this kind of interdependency. One accountable team manages all nine workstreams — from FDA strategy alignment and protocol development through site activation, patient enrollment, data management, and delivery of a submission-ready clinical evidence package — within a 12-month timeline. That structure only works when foundational documents like the IB are treated as program-critical deliverables, not administrative tasks.
Sponsors who arrive with a complete, current IB move faster through regulatory review in Panama, El Salvador, Chile, and the Dominican Republic, where approvals run 30 to 90 days under normal conditions. Sponsors who arrive without one add weeks or months to a timeline that was already tight.
What a Strong IB Looks Like in Practice
A well-constructed IB for a first-in-human medical device trial typically runs 30 to 80 pages, depending on the volume of preclinical data. It should be organized so that a principal investigator who has never seen the device can read the summary section and come away with a clear understanding of the product, its intended use, the key preclinical findings, and the anticipated risks — in under 20 minutes.
The non-clinical section should be honest about data gaps. If a particular toxicology study has not been completed, say so and explain why the available data is sufficient to justify proceeding. Regulators are accustomed to early-stage programs with incomplete datasets. What they are not accustomed to is sponsors who do not acknowledge what they do not yet know.
The guidance section at the end should be practical: what investigators should watch for, how to grade adverse events using a recognized scale, when to contact the sponsor, and when to stop dosing or use. This section is consistently underdeveloped in first-time sponsor IBs.
Regulatory Alignment Across Jurisdictions
Running a multi-country FIH trial means the IB must satisfy the requirements of each operating jurisdiction's regulatory authority. In Panama, that means MINSA and CNBI. In Chile, ISP and MINSAL. In El Salvador, SRS and CNEIS. Each authority may have specific formatting or language requirements, and the ethics committee at each site may request additional sections or clarifications.
Building a single IB that satisfies all applicable requirements from the start is far more efficient than drafting one version and adapting it reactively. Sponsors who have been through this process before know that the time invested in a rigorous initial IB pays back in faster approvals and fewer revision cycles.
Frequently Asked Questions
What is an investigator's brochure in clinical trials?
An investigator's brochure is a document compiled by the sponsor that summarizes all relevant clinical and non-clinical data about an investigational product. It gives investigators the information they need to understand the scientific rationale for the trial and to manage participant safety. It is required under ICH E6(R2) GCP guidelines for drug and biologic trials and serves an equivalent function in medical device studies.
When should a sponsor prepare the investigator's brochure?
The IB should be drafted in parallel with preclinical work, not after it concludes. Waiting until all studies are complete before starting the IB adds unnecessary time to your regulatory submission timeline. Draft the structure early and populate it as data becomes available.
Does the investigator's brochure need to be updated during the trial?
Yes. ICH E6(R2) requires that the IB be reviewed at least annually and updated whenever new information materially affects the risk-benefit assessment. Updated versions must be distributed to all active sites and ethics committees promptly.
Is an investigator's brochure required for medical device trials?
The IB as defined by ICH E6(R2) applies primarily to drug and biologic trials. For medical devices, the equivalent information is typically included in the IDE application or the Investigational Plan. That said, many medical device sponsors also prepare an IB-style document because ethics committees and international regulatory authorities often expect one.
What happens if the investigator's brochure is incomplete at the time of regulatory submission?
An incomplete IB can trigger requests for additional data from the regulatory authority or ethics committee, extending the review timeline. In jurisdictions where approvals can otherwise move quickly, a weak IB is frequently the primary cause of delays.
How long should an investigator's brochure be for a first-in-human trial?
For a first-in-human medical device or biologic trial, a well-constructed IB typically runs 30 to 80 pages depending on the volume of preclinical data available. The priority is completeness and clarity, not length. A concise, well-organized IB is more useful to investigators and reviewers than a lengthy one that buries the information that matters.
Does the investigator's brochure need to be translated for Latin American trials?
It depends on the country and the ethics committee's requirements. In some jurisdictions, an English-language IB is acceptable. In others, a Spanish translation is required. Sponsors should confirm language requirements for each operating jurisdiction before finalizing the document.
The investigator's brochure is not a formality. It is the scientific case for why your trial should proceed and the practical guide that keeps investigators and patients safe once it does. Get it right before you start — and keep it current throughout. If you are planning a first-in-human program and want to understand how the IB fits into the full regulatory and operational sequence, bioaccess® works with sponsors from the earliest stages of trial planning.
Leave a Reply